Driven by a passion for the wellbeing of animals, Regenesis Vet makes use of cutting-edge technology and advanced scientific research to produce results-oriented veterinary products.
Based in Cape Town, South Africa, Regenesis Vet was founded in 2018 by entrepreneur Alex Miszewski. A competitive showjumper with a love for horses, Alex was in her final year of high school when she cofounded her first successful company selling the world’s first orthotic for sports-horses. Two years later, while completing a Business Science Finance degree, Alex recruited the expertise of renowned expert veterinarians she worked with in the past and Regenesis Vet was founded.
Inspired by the injuries her own horse sustained during her show jumping career, Alex set out to build Regenesis Vet on the values of accessibility, affordability and hope.
When Alex’s horse suffered her near career-ending injury, she found herself in an unfortunate position she had seen many of her peers experience. From her experience with cutting-edge technology, she had seen how frustrating it could be for those who could not afford the available treatments but so badly needed it. Much of the available technology was not easily accessible, nor was it affordable. Concerned by the fact that there were so few affordable and practical long-term non-invasive regenerative options available, she set out to find a solution.
Her aim in starting Regenesis Vet was to help reduce the number of people succeeding her that ended up in a position where the solutions offered to them were inaccessible, unaffordable or impractical for long-term use. Based on these values of accessibility, affordability and hope that there is a different solution, Regenesis Vet was born.
With hard work and plenty of determination, Regenesis Vet developed the world’s first and only commercially available systemic regenerative equine treatment derived fully from a unique system of processing autologous blood. Subsequent to its development, the system has been worked on and is continuously being improved by leading biomedical scientists.
Regenesis Vet’s signature product, Regenesis EGF (Equine Growth Factors), was inspired by the remarkable results generated by growth factor therapy- a treatment growing in popularity among injured athletes and those undergoing post-operative care. Growth factor therapy makes use of specific growth factors carefully extracted from the blood to stimulate healing and regeneration of injured or damaged tendons, ligaments and joints.
Thanks to the proprietary activation agent enzyme solution developed by Regenesis Vet, the above can be achieved without damaging the desired growth factors. Once the process is complete, we are able to extract a concentrated serum which is rich in the targeted growth factors. The finished product promotes faster and better healing, a better immune response and quicker recovery after exercise. This FEI Legal and Jockey Club compliant treatment can be administered immediately or frozen for later use.
The serum offers a strong anti-inflammatory effect and is administered intravenously or injected into the muscle as per your vet’s recommendation. This works to speed up recovery, facilitate the healing process (after surgery or injury) and support tendon and cartilage repair. This ground-breaking treatment not only offers relief and a speedier recovery, but it also has the potential to prolong a horse’s show jumping or racing career, which often is cut short after injury. To find out how Regenesis Vet could be beneficial to your horse, speak directly to your vet. A full list of our veterinary partners can be found here.
Regenesis Vet is committed to the health and wellbeing of animals and continually strives to find better and more effective treatment solutions.
Founder & Managing Director
After matriculating from Herschel Girls’ school in 2016, Alexandra Miszewski went on to complete a BBusSci Finance degree at the University of Cape Town (UCT). She is currently completing a Masters of Finance degree, specialising in Investment Management, at the UCT Graduate School of Business.
Alexandra has always been passionate about problem-solving and entrepreneurship. Her entrepreneurial journey began in 2016 when she co-founded a company by the name of Equinetendon.com in South Africa. Since then, Equinetendon.com has grown from a small start-up with a few clients to a multinational company with a global presence.
As time went on, Alexandra’s interests moved towards Regenerative Medicine & Health Care, and in 2018 she co-founded Regenesis Vet – a company that has developed the first commercially-available systemic regenerative equine treatment derived fully from a unique system of processing autologous blood. In early 2021, she became the sole owner and shareholder.
After experiencing difficult challenges in her personal life in 2019, Alexandra decided that she wanted to do something to solve more African-centric problems, and with that, the medical device company Novita Biotechnology was born. With a unique business model of “hope”, Novita has been able to positively impact people, pets and the planet through the provision of affordable niche healthcare products in the Orthopaedic, Aesthetic, Veterinary & Ophthalmology spheres.
Through these ventures, Alexandra has been able pursue her passion for providing affordable and accessible innovations to as many people as possible, and in the process, making a positive impact in the lives of those who need it the most.
Dr Judey Pretorious
Head of Research & Development
Dr Judey Pretorius graduated with a degree in B.Sc. Biological Sciences from the North West University (Potchefstroom Campus) in 2003. Thereafter Dr Judey completed her honours degree in Biochemistry with the specific focus on paediatric metabolic diseases. In 2005 Dr Judey completed her M.Sc. in Biochemistry within the discipline of Mitochondrial Genetics and Molecular Biology. Dr Judey went on to complete her Ph.D in Pharmaceutical Chemistry (drug development and design) with the specific focus on neurodegenerative diseases and published an article “Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4phenylbytadien-1-yl) caffeine analogues” in the journal, i.e. Bioorganic and Medicinal Chemistry in 2008. Additional qualifications include post-doctoral fellowships at the University of Cape Town and the University of Witwatersrand in Human Biology and HIV drug design and development, respectively. Dr Judey also holds a diploma in Advanced Dermal Aesthetics for formulations of products for dermatological applications.
Upon the conclusion of her academic career, Dr Judey has since worked for multi-national and local Biotechnology and Pharmaceutical companies and has expertise and experience in the following accredited sector areas i.e. Pharmaceutical, Medical Devices, Cosmeceutical and Cell Biologics.
Dr Judey has special expertise in Scientific and Biomedical formulation and regulatory affairs of therapeutic products in respective disciplines such as cosmeceutical development, advanced wound care for acute, chronic and post-surgical wounds as well as cell culture and tissue engineering products, pharmaceutical drug development for both veterinary and human applications and customised dermatological formulas for respective therapies.
Dr Judey gained extensive experience as a Research and Development Formulation Scientist. She was also appointed as a consultant by SAHPRA to evaluate pharmaceutical dossiers drug master files for the registration of orthodox medicines for human and veterinarian use. She was responsible for Scientific and Biomedical formulation of therapeutic products of premium brands in respective disciplines.